The Journal of Clinical and Experimental Neuropsychology, published by Taylor & Francis Inc, stands as a pivotal resource in the realms of clinical psychology and neuropsychology. With an ISSN of 1380-3395 and an E-ISSN of 1744-411X, this journal has been a hallmark of scholarly excellence since its inception in 1985, continuing to shape the fields until 2024. It is renowned for its rigorous peer-reviewed articles and has garnered significant recognition, achieving a Q2 ranking in Clinical Psychology and Q3 rankings in various other relevant categories as of 2023. Serving as a bridge between clinical practice and experimental research, the journal underscores the critical role of neuropsychological assessment and intervention in enhancing mental health outcomes. Although not an open-access journal, it provides significant insights and empirical data that are crucial for researchers, clinicians, and students dedicated to advancing the understanding of cognitive functioning and psychological health. The journal's commitment to disseminating high-quality research contributes to its reputation and impact, making it a vital resource for those engaged in the study of neuropsychology and its clinical applications.

Alzheimer's & Dementia: Translational Research & Clinical Interventions, published by WILEY, is a premier open-access journal that has been at the forefront of innovations in the field of neurology and psychiatry since its inception in 2015. With an impressive impact factor reflecting its high-quality research contributions, this journal has been designated as Q1 in both Neurology (Clinical) and Psychiatry and Mental Health categories for 2023, ranking in the top percentiles of their respective Scopus fields. The journal aims to bridge the gap between research and clinical practice, promoting the translation of scientific discoveries into real-world applications for Alzheimer's disease and other dementias. Positioned in the United States, it is a valuable resource for researchers, clinicians, and students dedicated to advancing knowledge and treatment approaches in these critical areas. With its commitment to open access, the journal ensures that vital research is accessible to a broad audience, fostering collaboration and knowledge sharing across the global scientific community.

Dementia and Geriatric Cognitive Disorders Extra, published by KARGER in Switzerland, is an esteemed open-access journal dedicated to advancing research in the fields of cognitive neuroscience, geriatrics, and psychiatry. With a commitment to disseminating high-quality research since its inception in 2011, the journal plays a crucial role in highlighting innovative studies that address cognitive disorders associated with aging. As an open-access platform, it ensures that findings are accessible to a global audience, fostering collaboration and knowledge-sharing among researchers, professionals, and students alike. The journal has been recognized for its impact in Cognitive Neuroscience and Psychiatry and Mental Health, achieving a Q3 category ranking, indicating its reputable standing within these fields. By delivering cutting-edge insights and promoting interdisciplinary approaches, Dementia and Geriatric Cognitive Disorders Extra is instrumental in enhancing understanding and treatment of cognitive decline, making it a vital resource for anyone engaged in the study of aging and cognitive health.

BEHAVIOURAL NEUROLOGY is a distinguished open-access journal published by Hindawi Ltd, dedicated to advancing the field of neurology and neuropsychology since its inception in 1988. With ISSN: 0953-4180 and E-ISSN: 1875-8584, this journal provides a platform for innovative research and interdisciplinary studies that explore the intricate connections between behavior and neurological processes. Housed in the Netherlands, BEHAVIOURAL NEUROLOGY enjoys a commendable reputation, boasting impressive quartile rankings of Q2 in various medical and psychological categories, reflecting its significant contribution to the literature with a focus on clinical neurology and physiological psychology. The journal's rigorous peer-review process ensures that published works meet high academic standards, making it an essential resource for researchers, clinicians, and students seeking to deepen their understanding of neurological disorders and cognitive function. As of 2023, it ranks in the 80th percentile in neuropsychology, further underscoring its impact and relevance in the scientific community. For those interested in accessible knowledge, BEHAVIOURAL NEUROLOGY's commitment to open access facilitates the dissemination of groundbreaking research, allowing a wider audience to engage with critical advancements in the field.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

Cognitive Neuropsychiatry is a distinguished academic journal published by Routledge Journals, Taylor & Francis Ltd, dedicated to the intersection of cognitive neuroscience and psychiatry. With a strong commitment to advancing knowledge in these rapidly evolving fields, this journal provides a platform for high-quality, peer-reviewed research that explores cognitive processes underlying psychiatric disorders. Aiming to bridge gaps between neuroscience and clinical practice, it serves as an essential resource for researchers, professionals, and students alike. As evidenced by its performance metrics, the journal ranks in the Q2 quartile for Psychiatry and Mental Health, and Q3 for Cognitive Neuroscience, showcasing its relevance and growing impact, particularly among a competitive audience. While it does not currently offer open access options, Cognitive Neuropsychiatry remains a vital outlet for disseminating impactful findings, offering insights that shape contemporary psychiatric understanding and interventions.

Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

JPAD - Journal of Prevention of Alzheimer’s Disease, published by Springer Basel AG, is a premier academic journal dedicated to advancing research in the critical field of Alzheimer’s disease prevention. Its impactful contributions to the fields of neurology, psychiatry, and mental health have led it to achieve a Q1 ranking in multiple categories, including neurology (clinical) and psychiatry and mental health. Since its inception in 2017, JPAD has become an essential platform for researchers and professionals aiming to stay at the forefront of developments in Alzheimer’s disease research, prevention strategies, and innovative therapies. The journal provides a valuable open access option for disseminating high-quality research to a global audience, enhancing its visibility and impact. With its strategic focus and rigorous peer-review process, JPAD is committed to fostering collaboration and knowledge exchange among scientists, clinicians, and practitioners, ultimately contributing to the global effort to combat Alzheimer's disease.

The Journal of Clinical Neurology, published by the Korean Neurological Association, is a prominent open-access journal that has been disseminating crucial findings in the field of neurology since its inception in 2008. With an ISSN of 1738-6586 and an E-ISSN of 2005-5013, this journal provides a vital platform for researchers and clinicians to share innovative research, reviews, and case studies that advance understanding and treatment of neurological disorders. The journal has established its reputation, achieving a Q3 ranking in Neurology and a Q2 ranking in Clinical Neurology in 2023, placing it among the noteworthy sources in the medical community. With its open-access format since 2011, it facilitates broad dissemination of knowledge to both the scientific community and the public, supporting the journal's mission to enhance clinical practice and promote neurological health in South Korea and beyond. As of October 2023, it holds influential Scopus ranks, reflecting its impact and relevance in the ever-evolving landscape of neuroscience. Researchers, professionals, and students alike are encouraged to contribute to and engage with the ongoing discourse by submitting their work and accessing a wealth of resources through this esteemed publication.

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.